Vector Science and Therapeutics Corp. Announces Stock Options Grant
Mequon, Wisconsin – (Newsfile Corp. – September 25, 2026) – Vector Science and Therapeutics Corp. (TSXV: PAIN) (“Vector” or the “Company”) has announced the approval of a grant of 150,000 stock options (the “Options”) to one of the Company’s Officers, as per its stock option plan.
- Vesting: The Options will vest in 25% tranches over three years.
- Exercise Price: C$1.80.
- Exercise Period: Options are exercisable for five years from the grant date.
This grant is subject to approval from the TSX Venture Exchange.
Stock Option Plan Overview
Currently, 7,336,610 common shares are reserved for issuance under the stock option plan, with 8,388,183 options remaining available for issuance.
About Vector Science and Therapeutics Corp.
Headquartered in Mequon, Wisconsin, Vector develops novel biomechanical devices and localized drug delivery platforms aimed at facilitating site-directed interventions where precision is crucial and systemic risks must be minimized. The Company’s shares are listed on the TSX Venture Exchange under the symbol PAIN. More information can be found on www.vectorscience.co.
Disclaimer: The TSX Venture Exchange and its Regulation Services Provider do not accept responsibility for the adequacy or accuracy of this release.
U.S. Advisory
The securities mentioned have not and will not be registered under the U.S. Securities Act of 1933. They have been offered and sold outside the U.S. to eligible investors under Regulation S. There are restrictions on the offering, sale, or resale of these securities in the United States unless registered or exempt from such registration.
For more details, visit the source: Newsfile Release
